Loading clinical trials...
Loading clinical trials...
A Phase 3 Safety and Immunogenicity Trial of the VLP-Based Chikungunya Virus Vaccine PXVX0317 in Adults ≥65 Years of Age
Conditions
Interventions
CHIKV VLP/adjuvant
Placebo
Locations
10
United States
Suncoast Research Associates, LLC
Miami, Florida, United States
Panax Clinical Research
Miami Lakes, Florida, United States
Global Clinical Research Professionals (GCP)
St. Petersburg, Florida, United States
AMR Kansas City
Kansas City, Missouri, United States
Rochester Clinical Research, Inc.
Rochester, New York, United States
Coastal Carolina Research Center
North Charleston, South Carolina, United States
Start Date
May 12, 2022
Primary Completion Date
June 19, 2023
Completion Date
August 8, 2023
Last Updated
December 13, 2024
NCT05072080
NCT02861586
NCT02562482
Lead Sponsor
Bavarian Nordic
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions